Takeo Yoshihara

ORCID: 0000-0003-0131-9294
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Helicobacter pylori-related gastroenterology studies
  • Eosinophilic Esophagitis
  • Esophageal and GI Pathology
  • Immunodeficiency and Autoimmune Disorders
  • Celiac Disease Research and Management
  • Clusterin in disease pathology
  • Gastrointestinal Tumor Research and Treatment
  • Glycosylation and Glycoproteins Research
  • Pancreatitis Pathology and Treatment
  • Monoclonal and Polyclonal Antibodies Research
  • Galectins and Cancer Biology
  • Gastrointestinal motility and disorders
  • Lung Cancer Diagnosis and Treatment
  • Long-Term Effects of COVID-19
  • Sphingolipid Metabolism and Signaling
  • Immune Cell Function and Interaction
  • Gut microbiota and health
  • Colorectal Cancer Treatments and Studies
  • Oral Health Pathology and Treatment
  • Colorectal Cancer Screening and Detection
  • Pancreatic and Hepatic Oncology Research

Osaka University
1982-2025

Hudson Institute
2020

Saiseikaisenri Hospital
2015

Abstract Background We developed an artificial intelligence (AI)-based endoscopic ultrasonography (EUS) system for diagnosing the invasion depth of early gastric cancer (EGC), and we evaluated performance this system. Methods A total 8280 EUS images from 559 EGC cases were collected 11 institutions. Within dataset, 3451 (285 cases) one institution used as a development dataset. The AI model consisted segmentation classification steps, followed by CycleGAN method to bridge differences in...

10.1007/s00535-024-02102-1 article EN cc-by Journal of Gastroenterology 2024-05-07

Abstract Background We developed a machine learning (ML) model to predict the risk of lymph node metastasis (LNM) in patients with early gastric cancer (EGC) who did not meet existing Japanese endoscopic curability criteria and compared its performance that most common clinical scoring system, eCura system. Methods used data from 4,042 consecutive EGC 21 institutions underwent submucosal dissection (ESD) and/or surgery between 2010 2021. All resected EGCs were histologically confirmed...

10.1007/s10120-024-01511-8 article EN cc-by Gastric Cancer 2024-05-25

Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced responses exaggerate colitis mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration their feces, accompanied by a higher relative abundance of...

10.1084/jem.20211291 article EN cc-by The Journal of Experimental Medicine 2022-05-24

Abstract There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and regarding optimal strategies after therapy. We conducted a multi-institutional retrospective study patients UC treated tacrolimus or between January 2010 March 2019. The proportion clinical at week 8 cumulative colectomy-free rate were examined using propensity score matching analysis. predictors for colectomy also...

10.1038/s41598-024-77365-y article EN cc-by Scientific Reports 2025-01-02

ABSTRACT Cancer‐associated fibroblasts (CAFs), a major component of the tumor microenvironment, play an important role in progression. Colon cancer cells deficient p53 activate and enhance fibroblast‐mediated growth. Meflin is CAF marker capable inhibiting In this study, we investigated using human cell lines (colon HCT116 CCD‐18Co) clinical specimens. TP53‐suppressed (HCT116 sh ) cocultured with CCD‐18Co showed significantly faster proliferation than control cells. xenograft experiments,...

10.1111/cas.70026 article EN cc-by-nc Cancer Science 2025-04-16

Abstract Background and Aim Lipids play important roles in inflammation may be involved the pathophysiology of inflammatory bowel disease (IBD). Here, we evaluated characteristics plasma lipid profile patients with IBD. Methods Plasma samples were collected from 20 Crohn's (CD), ulcerative colitis (UC), 10 healthy volunteers (HVs) after overnight fasting. The subjects men between 49 years age no history hyperlipidemia. A total 698 molecular species 22 classes analyzed by ultra‐performance...

10.1111/jgh.15067 article EN Journal of Gastroenterology and Hepatology 2020-04-14

Abstract The outcomes of patients with elderly onset (EO) inflammatory bowel disease (IBD) treated anti-tumor necrosis factor (TNF) remains uncertain. present study evaluated the efficacy and safety anti-TNF treatment for bio-naïve EO-IBD. Elderly were defined as those 60 years older, further divided into EO (Elderly-EO) non-elderly (Elderly-NEO). A total 432 enrolled in this multicenter observational study, comprising 55 Elderly-EO (12.7%), 25 Elderly-NEO (5.8%), 352 under age (Non-elderly,...

10.1038/s41598-022-09455-8 article EN cc-by Scientific Reports 2022-03-29

Summary Background Endoscopic healing (EH) is a therapeutic target in ulcerative colitis (UC). However, even patients who have achieved EH relapse frequently. Aims To investigate the association between recent steroid use and risk UC with EH. Methods This multi‐centre cohort study included 1212 confirmed (Mayo endoscopic subscore ≤1). We excluded current systemic or history of advanced therapy. divided into group (last within 1 year; n = 59) non‐recent steroid‐naïve ( 1153). followed for 2...

10.1111/apt.18013 article EN Alimentary Pharmacology & Therapeutics 2024-04-23

Many reports indicate that a high-serum trough level of anti-tumor necrosis factor (TNF) agents is required for sustained remission in patients with Crohn's disease The pharmacokinetics anti-TNF inflamed intestinal tissue, however, not well investigated. We investigated the association between tissue concentration and long-term outcome. This was prospective single-center study enrolled 25 who were administered infliximab or adalimumab. All participants underwent endoscopy 2 weeks after...

10.1097/mib.0000000000001260 article EN Inflammatory Bowel Diseases 2017-09-25

The morphological diagnosis of microvessels on the surface superficial esophageal squamous cell carcinomas using magnifying endoscopy with narrow-band imaging is widely used in clinical practice. Nevertheless, inconsistency, even among experts, remains a problem. We constructed convolutional neural network-based computer-aided system to classify and evaluated its diagnostic performance.In this retrospective study, cropped images from carcinoma lesions was as dataset. All were assessed by...

10.1111/jgh.15479 article EN Journal of Gastroenterology and Hepatology 2021-03-10

Abstract Background and Aim Following treatment of superficial esophageal squamous cell carcinoma (ESCC), surveillance for a second primary malignancy (SPM) is necessary. However, detailed evidence regarding the timing prognosis SPMs insufficient. We aimed to clarify details their effects on patient outcomes. Methods This retrospective, multicenter study involved 11 hospitals. Patients with ESCC curatively resected using endoscopic submucosal dissection between May 2005 December 2012, were...

10.1002/cam4.7242 article EN cc-by Cancer Medicine 2024-05-01

Serum leucine-rich alpha-2 glycoprotein (LRG) can monitor disease activities during biologics treatment in patients with inflammatory bowel (IBD). It is unclear whether the pretreatment serum LRG level predict clinical effectiveness including trough levels of ustekinumab IBD. This multicenter prospective cohort study included 184 (Crohn's disease, 104; ulcerative colitis, 80) who received (n = 119) or anti-tumor necrosis factor 65) between January 2019 and March 2023. Multivariate logistic...

10.1038/s41598-024-80285-6 article EN cc-by-nc-nd Scientific Reports 2024-11-29

Objectives The aim of the present study was to assess appropriate administration dose non-steroidal anti-inflammation drugs prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Importantly, 100 mg diclofenac recommended in Western countries has not been permitted Japan. Design A retrospective study. Settings single centre Participants This enrolled patients who underwent ERCP at Department Gastroenterology, Osaka Saiseikai Senri Hospital, from April 2011 through...

10.1136/bmjopen-2014-006950 article EN cc-by-nc BMJ Open 2015-03-01

Abstract Background The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal jejunal adenocarcinoma (mDJA) are unclear. present study aimed to evaluate the bevacizumab explore immunohistochemical markers that can predict mDJA. Methods This multicentre included histologically confirmed small bowel who received palliative from 2008 2017 at 15 hospitals. Immunostaining was performed vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin,...

10.1186/s12885-021-08724-5 article EN cc-by BMC Cancer 2021-08-31

Background and aim Environmental factors are associated with onset course of inflammatory bowel disease (IBD). Our previous study by about 1,100 IBD patients revealed half the experienced seasonal exacerbation disease. We investigated seasonality fecal microbiota composition patients. Methods Fecal samples were consecutively collected in each season from outpatients healthy controls between November 2015 April 2019. Participants who treated full elemental diet or antibiotics within 6 months...

10.1371/journal.pone.0283880 article EN cc-by PLoS ONE 2023-04-18

Cancer‑associated fibroblasts (CAFs) are pivotal in tumor progression. TP53‑deficiency cancer cells is associated with robust stromal activation. The apelin‑apelin receptor (APJ) system has been implicated suppressing fibroblast‑to‑myofibroblast transition non‑neoplastic organ fibrosis. present study aimed to elucidate the oncogenic role of apelin‑APJ fibroblasts. APJ expression and effect suppression were investigated for p53 status using human cell lines (TP53‑wild colon cancer, HCT116,...

10.3892/ijo.2023.5587 article EN cc-by-nc-nd International Journal of Oncology 2023-11-02

Abstract Background and Aim Galectin‐1 plays a protective role against colitis by binding with polylactosamine structures on macrophages in β‐1,4‐galactosyltransferase I‐deficient mice, but the precise function of galectin‐1 remains unknown. In present study, we investigated anti‐inflammatory to ameliorate ulcerative both animal model human tissue samples. Methods The expression colonic tissues patients was evaluated immunohistochemistry. Cytokine production mouse bone marrow‐derived (BMDMs)...

10.1111/jgh.15097 article EN Journal of Gastroenterology and Hepatology 2020-05-19

Yoshihara, Takeo; Sakamori, Ryotaro; Furuta, Kunimaro; Shigekawa, Minoru; Yamada, Ryoko; Kodama, Takahiro; Hikita, Hayato; Yakushijin, Takayuki; Tatsumi, Tomohide; Sakata, Yasushi; Eguchi, Hidetoshi; Sawa, Yoshiki; Takehara, Tetsuo Author Information

10.1002/hep.29758 article EN Hepatology 2017-12-24
Coming Soon ...